Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study

[1]  V. Nincevic,et al.  Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes , 2019, International journal of molecular sciences.

[2]  K. Wu,et al.  Update of pathophysiology and management of diabetic kidney disease. , 2018, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  N. Nakamura,et al.  Prognostic significance of day-by-day variability of home blood pressure on progression to macroalbuminuria in patients with diabetes , 2017, Journal of hypertension.

[4]  N. Nakamura,et al.  Maximum home blood pressure is a useful indicator of diabetic nephropathy in patients with type 2 diabetes mellitus: KAMOGAWA-HBP study , 2017, Diabetes & vascular disease research.

[5]  Hynek Pikhart,et al.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants , 2017, The Lancet.

[6]  L. Rédaction,et al.  World Health Statistics 2016: monitoring health for the SDGs, sustainable development goals. WHOGeneva (2016). ISBN 978 92 4 156526 4 , 2016 .

[7]  O. Pedersen,et al.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.

[8]  K. Kario,et al.  Morning Blood Pressure Surge as a Predictor of Development of Chronic Kidney Disease , 2016, Journal of clinical hypertension.

[9]  W. Cushman,et al.  Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes , 2016, Diabetes Care.

[10]  N. Nakamura,et al.  Optimal home SBP targets for preventing the progression of diabetic nephropathy in patients with type 2 diabetes mellitus , 2015, Journal of hypertension.

[11]  Y. Tomino,et al.  The Prevalence and Management of Diabetic Nephropathy in Asia , 2015, Kidney Diseases.

[12]  M. Woodward,et al.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.

[13]  L. Ruilope,et al.  The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow‐Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation , 2014, Journal of the American Heart Association.

[14]  Masaaki Inaba,et al.  Association Between Glycemic Control and Morning Blood Pressure Surge With Vascular Endothelial Dysfunction in Type 2 Diabetic Patients , 2014, Diabetes Care.

[15]  T. Ninomiya,et al.  Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes , 2014, Clinical and Experimental Nephrology.

[16]  S. Fuchs,et al.  Home Blood Pressure Monitoring Is Better Predictor of Cardiovascular Disease and Target Organ Damage than Office Blood Pressure: A Systematic Review and Meta-Analysis , 2013, Current Cardiology Reports.

[17]  Kazuomi Kario,et al.  Nighttime Home Blood Pressure and the Risk of Hypertensive Target Organ Damage , 2012, Hypertension.

[18]  J. Staessen,et al.  Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure , 2012, Hypertension Research.

[19]  K. Kario,et al.  Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment. , 2012, American journal of hypertension.

[20]  N. Nakamura,et al.  The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus , 2011, Hypertension Research.

[21]  J. Chan,et al.  Treatment and landmark clinical trials for renoprotection. , 2011, Contributions to nephrology.

[22]  N. Nakamura,et al.  Uncontrolled home blood pressure in the morning is associated with nephropathy in Japanese type 2 diabetes , 2011, Heart and Vessels.

[23]  Rodica Pop-Busui,et al.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.

[24]  Rury R Holman,et al.  Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.

[25]  M. Cooper,et al.  UKPDS and the legacy effect. , 2008, The New England journal of medicine.

[26]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[27]  J. Lewis,et al.  Microalbuminuria in Type 2 Diabetes and Hypertension , 2008, Diabetes Care.

[28]  A. Kashiwagi,et al.  Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. , 2007, Diabetes research and clinical practice.

[29]  A. Jula,et al.  Home-measured blood pressure is more strongly associated with electrocardiographic left ventricular hypertrophy than is clinic blood pressure: the Finn-HOME study , 2007, Journal of Human Hypertension.

[30]  Andrew Shennan,et al.  Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol , 2006, Blood pressure monitoring.

[31]  H. Kramer,et al.  Progression of kidney disease in type 2 diabetes – beyond blood pressure control: an observational study , 2005, BMC nephrology.

[32]  B. Brenner,et al.  Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. , 2003, Archives of internal medicine.

[33]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[34]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[35]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[36]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[37]  J. Widimský,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1998, Diabetes Care.

[38]  J. Born,et al.  Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. , 1997, Hypertension.

[39]  S. Willich,et al.  Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. , 1987, The New England journal of medicine.

[40]  I. Ford,et al.  Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy 20-Year Follow-Up of West of Scotland Coronary Prevention Study , 2016 .